Skip to main content
SpringerLink
Log in
Book cover

Cardio-Oncology pp 105–123Cite as

Treatment of Hypertension in Patients Receiving Cancer Therapy

  • Chapter
  • First Online:

Abstract

Hypertension is a common cardiovascular disease associated with high morbidity and mortality when left untreated. As the incidence of hypertension increases in the general population, its prevalence among oncology patients continues to rise. Some of this can be attributed to common risks among hypertension and cancer, including obesity, smoking, and family history; however, some of the therapies used in the pharmacologic treatment of cancer also have direct cardiovascular effects leading to hypertension. The best studied of these drugs include the VEGF and other angiogenesis inhibitors, alkylating agents, and taxanes. Medications commonly used for other diseases, including immunosuppressive agents, are also associated with hypertension. A comprehensive review of the risk factors for hypertension and the medications associated with hypertension is necessary in order to facilitate successful treatment. The contemporary cardio-oncologist has an increasing arsenal of medications, including thiazide-type diuretics, calcium channel blockers, ACE inhibitors, and aldosterone receptor blockers at his or her disposal. The most successful treatment plan allows the continuation of chemotherapy while preventing the secondary damage of untreated hypertension.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Centers for Disease C, Prevention. Vital signs: prevalence, treatment, and control of hypertension–United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011;60(4):103–8.

    Google Scholar 

  2. Solimando DA. Paclitaxel package insert. Cancer Invest. 1997;15(5):503.

    Article  CAS  PubMed  Google Scholar 

  3. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep. 2007;9(4):320–8.

    Article  CAS  PubMed  Google Scholar 

  4. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel Jr EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7.

    Article  CAS  PubMed  Google Scholar 

  5. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  PubMed  Google Scholar 

  7. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18(8):1725–32.

    Article  CAS  PubMed  Google Scholar 

  8. Bursztyn M, Zelig O, Or R, Nagler A. Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study. Transplantation. 1997;63(7):1034–6.

    Article  CAS  PubMed  Google Scholar 

  9. Yoon SS, Ostchega Y, Louis T. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999–2008. NCHS Data Brief. 2010;48:1–8.

    Google Scholar 

  10. Cherry DK, Woodwell DA. National ambulatory medical care survey: 2000 summary. Adv Data. 2002;(328):1–32.

    Google Scholar 

  11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

    Article  CAS  PubMed  Google Scholar 

  12. SPRINT Research Group, Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff Jr DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

    Article  Google Scholar 

  13. National Cancer Institute (U.S.). Common terminology criteria for adverse events (CTCAE), Rev ed. Bethesda, MD: U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009. 194p.

    Google Scholar 

  14. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists C. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356(9246):1955–64.

    Google Scholar 

  15. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35(2):539–43.

    Article  CAS  PubMed  Google Scholar 

  16. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Archiv Intern Med. 1997;157(6):657–67.

    Google Scholar 

  17. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35(2):544–9.

    Article  CAS  PubMed  Google Scholar 

  18. Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001;135(12):1019–28.

    Article  CAS  PubMed  Google Scholar 

  19. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on sodium and blood pressure : a critical review of current scientific evidence. Hypertension. 2000;35(4):858–63.

    Article  CAS  PubMed  Google Scholar 

  20. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2000;35(3):838–43.

    Article  CAS  PubMed  Google Scholar 

  21. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136(7):493–503.

    Article  PubMed  Google Scholar 

  22. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38(5):1112–7.

    Article  CAS  PubMed  Google Scholar 

  23. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.

    Article  CAS  PubMed  Google Scholar 

  24. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273–86.

    Article  CAS  PubMed  Google Scholar 

  25. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328–35.

    Article  CAS  PubMed  Google Scholar 

  26. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.

    Article  CAS  PubMed  Google Scholar 

  27. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792–9.

    Article  CAS  PubMed  Google Scholar 

  28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

    Article  CAS  PubMed  Google Scholar 

  29. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697–705.

    Article  CAS  PubMed  Google Scholar 

  30. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007;27(5B):3465–70.

    CAS  PubMed  Google Scholar 

  31. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30(5 Suppl 16):117–24.

    Article  CAS  PubMed  Google Scholar 

  32. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–91.

    Article  CAS  PubMed  Google Scholar 

  33. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28(11):1779–802.

    Article  CAS  PubMed  Google Scholar 

  35. Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 2013;53:161–85.

    Article  CAS  PubMed  Google Scholar 

  36. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105(3):986–93.

    Article  CAS  PubMed  Google Scholar 

  37. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  38. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26(11):1810–6.

    Article  CAS  PubMed  Google Scholar 

  39. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24.

    Article  CAS  PubMed  Google Scholar 

  40. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.

    Article  CAS  PubMed  Google Scholar 

  41. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–24.

    Article  CAS  PubMed  Google Scholar 

  42. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, et al. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology. 2007;73(3–4):204–9.

    Article  CAS  PubMed  Google Scholar 

  44. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99(1):159–65.

    CAS  PubMed  Google Scholar 

  45. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505–12.

    Article  CAS  PubMed  Google Scholar 

  46. Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol. 2008;31(2):182–7.

    Article  CAS  PubMed  Google Scholar 

  47. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–23.

    Article  CAS  PubMed  Google Scholar 

  48. Qi WX, Lin F, Sun YJ, Tang LN, He AN, Yao Y, et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol. 2013;71(2):431–9.

    Article  CAS  PubMed  Google Scholar 

  49. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, et al. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011;58(1):85–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother. 2006;40(12):2278–9.

    Article  PubMed  Google Scholar 

  51. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Dhaun N, Webb DJ. Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun? Hypertension. 2010;56(4):575–7.

    Article  CAS  PubMed  Google Scholar 

  53. Aparicio-Gallego G, Afonso-Afonso FJ, Leon-Mateos L, Firvida-Perez JL, Vazquez-Estevez S, Lazaro-Quintela M, et al. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs. 2011;22(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  54. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis. 2004;7(3):193–201.

    Article  CAS  PubMed  Google Scholar 

  55. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006;24(9):1363–9.

    Article  CAS  PubMed  Google Scholar 

  56. Mir O, Mouthon L, Alexandre J, Mallion JM, Deray G, Guillevin L, et al. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst. 2007;99(1):85–6.

    Article  PubMed  Google Scholar 

  57. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Graves SW, Eder JP, Schryber SM, Sharma K, Brena A, Antman KH, et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci. 1989;77(5):501–7.

    Article  CAS  PubMed  Google Scholar 

  59. Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, et al. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol. 2008;10(1):35–46.

    Article  CAS  PubMed  Google Scholar 

  60. Salvatorelli E, Menna P, Cascegna S, Liberi G, Calafiore AM, Gianni L, et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther. 2006;318(1):424–33.

    Article  CAS  PubMed  Google Scholar 

  61. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–803.

    Article  CAS  PubMed  Google Scholar 

  62. Jerian SM, Sarosy GA, Link Jr CJ, Fingert HJ, Reed E, Kohn EC. Incapacitating autonomic neuropathy precipitated by taxol. Gynecol Oncol. 1993;51(2):277–80.

    Article  CAS  PubMed  Google Scholar 

  63. Loughran Jr TP, Deeg HJ, Dahlberg S, Kennedy MS, Storb R, Thomas ED. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. Br J Haematol. 1985;59(3):547–53.

    Article  PubMed  Google Scholar 

  64. June CH, Thompson CB, Kennedy MS, Loughran Jr TP, Deeg HJ. Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients. Transplantation. 1986;41(1):47–51.

    Article  CAS  PubMed  Google Scholar 

  65. Kone BC, Whelton A, Santos G, Saral R, Watson AJ. Hypertension and renal dysfunction in bone marrow transplant recipients. Q J Med. 1988;69(260):985–95.

    CAS  PubMed  Google Scholar 

  66. Textor SC, Forman SJ, Bravo EL, Carlson J. De novo accelerated hypertension during sequential cyclosporine and prednisone therapy in normotensive bone marrow transplant recipients. Transplant Proc. 1988;20(3 Suppl 3):480–6.

    CAS  PubMed  Google Scholar 

  67. Grossman E, Messerli FH. Secondary hypertension: interfering substances. J Clin Hypertens. 2008;10(7):556–66.

    Article  CAS  Google Scholar 

  68. Grossman E, Messerli FH. High blood pressure. A side effect of drugs, poisons, and food. Arch Intern Med. 1995;155(5):450–60.

    Article  CAS  PubMed  Google Scholar 

  69. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40(15):2201–16.

    Article  CAS  PubMed  Google Scholar 

  70. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59(3):538–48.

    Article  CAS  PubMed  Google Scholar 

  71. Novak BL, Force RW, Mumford BT, Solbrig RM. Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature. Pharmacotherapy. 2003;23(2):265–9.

    Article  PubMed  Google Scholar 

  72. Ketch T. Four faces of baroreflex failure: hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia. Circulation. 2002;105(21):2518–23.

    Article  PubMed  Google Scholar 

  73. Shapiro MH, Ruiz-Ramon P, Fainman C, Ziegler MG. Light-headedness and defective cardiovascular reflexes after neck radiotherapy. Blood Press Monit. 1996;1(1):81–5.

    CAS  PubMed  Google Scholar 

  74. Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M, et al. The neuropathic postural tachycardia syndrome. N Engl J Med. 2000;343(14):1008–14.

    Article  CAS  PubMed  Google Scholar 

  75. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015;9(6):453–98.

    Google Scholar 

  76. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.

    Article  CAS  PubMed  Google Scholar 

  77. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol. 2007;18(6):1117.

    Article  CAS  PubMed  Google Scholar 

  78. Markman M. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf. 2003;2(2):141–6.

    Article  CAS  PubMed  Google Scholar 

  79. Hung CH, Chan SH, Chu PM, Tsai KL. Docetaxel facilitates endothelial dysfunction through oxidative stress via modulation of protein kinase C beta: the protective effects of sotrastaurin. Toxicol Sci. 2015;145(1):59–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. National High Blood Pressure Education Program. Arch Intern Med. 1990;150(2):280–3.

    Article  CAS  PubMed  Google Scholar 

  81. Dawidson I, Rooth P, Fisher D, Fry WR, Alway C, Coorpender L, et al. Verapamil ameliorates acute cyclosporine A (CsA) nephrotoxicity and improves immunosuppression after cadaver renal transplantation. Transplant Proc. 1989;21(1 Pt 2):1511–3.

    CAS  PubMed  Google Scholar 

  82. Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc. 1994;69(12):1182–93.

    Article  CAS  PubMed  Google Scholar 

  83. Cifkova R, Hallen H. Cyclosporin-induced hypertension. J Hypertens. 2001;19(12):2283–5.

    Article  CAS  PubMed  Google Scholar 

  84. Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol. 2000;35(3 Suppl 1):S7–11.

    Article  CAS  PubMed  Google Scholar 

  85. Manzia TM, De Liguori CN, Orlando G, Toti L, De Luca L, D'Andria D, et al. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proc. 2005;37(6):2616–7.

    Article  CAS  PubMed  Google Scholar 

  86. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16 Suppl 1:121–4.

    Article  CAS  PubMed  Google Scholar 

  87. Luft FC. Erythropoietin and arterial hypertension. Clin Nephrol. 2000;53(1 Suppl):S61–4.

    CAS  PubMed  Google Scholar 

  88. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003;104(4):488–95.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology, Brigham and Women’s Hospital, Boston, MA, USA

    Aaron P. Kithcart

  2. Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Milano, Italy

    Giuseppe Curigliano

  3. Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, TN, USA

    Joshua A. Beckman

Authors
  1. Aaron P. Kithcart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Curigliano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joshua A. Beckman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron P. Kithcart .

Editor information

Editors and Affiliations

  1. Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA

    Gretchen G. Kimmick

  2. Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Daniel J. Lenihan

  3. Maine Medical Center, Cardiovascular Institute, Portland, Maine, USA

    Douglas B. Sawyer

  4. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

    Erica L. Mayer

  5. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA

    Dawn L. Hershman

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

(PPTX 462 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kithcart, A.P., Curigliano, G., Beckman, J.A. (2017). Treatment of Hypertension in Patients Receiving Cancer Therapy. In: Kimmick, G., Lenihan, D., Sawyer, D., Mayer, E., Hershman, D. (eds) Cardio-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-43096-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43096-6_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43094-2

  • Online ISBN: 978-3-319-43096-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation